SCHEMBL2532833

SCHEMBL2532833

CCOC(=O)c1ccc(/N=C/c2ccccc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.71
CA2 P00918 5/20 0.71
GAA P10253 2/20 0.59
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 5/20 0.55
ALDH1A1 P00352 5/20 0.55
HPGD P15428 4/20 0.55
F2 P00734 1/20 0.55
HIF1A Q16665 1/20 0.55
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
KDM4E B2RXH2 2/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
PPARG P37231 1/20 0.52
CA12 O43570 1/20 0.50
ESR1 P03372 1/20 0.50
CA7 P43166 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2532836 1.00 CA1 (0.71) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL9436819 0.92 CA2 (0.60) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL12416869 0.87 CA2 (0.56) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL12416615 0.87 CA2 (0.72) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL11257648 0.86 CA1 (0.55) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL2535701 0.86 PTPN1 (0.56) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL2535703 0.86 PTPN1 (0.56) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL10388734 0.85 CA1 (0.51) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL10388733 0.85 CA1 (0.51) CA1CA2GAASMN1; SMN2MAPT
SCHEMBL12416800 0.85 S100B (0.58) CA1CA2GAASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558449-B1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-05 EP disclosed
US-8586747-B2 3,3-dimethyl tetrahydroquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2013-11-19 US disclosed
EP-2558449-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
US-20130023518-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES Hoffmann-La Roche Inc (US) 2013-01-24 US disclosed
US-8344137-B2 3,3-dimethyl tetrahydroquinoline derivatives HOFFMAN-LA ROCHE INC. (US) 2013-01-01 US disclosed
WO-2011128251-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
US-20110257151-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES HUA MEDICINE (KY) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257151-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES QDPR, PRMT3, PRMT1 CA1 4320/4885CA2 1889/4885GAA 3991/4885
US-20130023518-A1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES QDPR, PRMT3, PRMT1 CA1 4320/4885CA2 1889/4885GAA 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.